Gary R Hudes

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Signaling inhibitors in the treatment of prostate cancer
    Gary R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Invest New Drugs 20:159-72. 2002
  2. ncbi Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1301-6. 2003
  3. ncbi Treatments for improving survival of patients with prostate cancer
    Alice K David
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Drugs Aging 20:683-99. 2003
  4. doi Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma
    Gary R Hudes
    Genitourinary Malignancies Program, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Semin Oncol 36:S26-36. 2009
  5. doi A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
    Gary Hudes
    Genitourinary Malignancies Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
    Invest New Drugs 31:669-76. 2013
  6. doi Targeting mTOR in renal cell carcinoma
    Gary R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer 115:2313-20. 2009
  7. ncbi Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
  8. ncbi Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network
    Naomi B Haas
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 98:1837-41. 2003
  9. ncbi Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model
    Raymond S McDermott
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Support Oncol 4:524-9. 2006
  10. ncbi mTOR as a target for therapy of renal cancer
    Gary R Hudes
    Genitourinary Malignancies Program, Fox Chase Cancer Center, Philadelphia, PA, USA
    Clin Adv Hematol Oncol 5:772-4. 2007

Collaborators

Detail Information

Publications17

  1. ncbi Signaling inhibitors in the treatment of prostate cancer
    Gary R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Invest New Drugs 20:159-72. 2002
    ....
  2. ncbi Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1301-6. 2003
    ....
  3. ncbi Treatments for improving survival of patients with prostate cancer
    Alice K David
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Drugs Aging 20:683-99. 2003
    ..Only the results of ongoing randomised trials can definitely establish that more patients with locally advanced and metastatic prostate cancer are living longer...
  4. doi Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma
    Gary R Hudes
    Genitourinary Malignancies Program, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Semin Oncol 36:S26-36. 2009
    ..Current trials are investigating the use of temsirolimus in sequence or in combination with other targeted agents to further improve outcomes...
  5. doi A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
    Gary Hudes
    Genitourinary Malignancies Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
    Invest New Drugs 31:669-76. 2013
    ..Conclusion These results suggest that siltuximab in combination with docetaxel is safe and shows preliminary efficacy in patients with CRPC, although alternative siltuximab schedules may be better tolerated for future studies...
  6. doi Targeting mTOR in renal cell carcinoma
    Gary R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer 115:2313-20. 2009
    ..Laboratory studies indicate that these resistance mechanisms could be countered by using other targeted agents in combination with mTOR inhibitors...
  7. ncbi Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
    ..Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease...
  8. ncbi Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network
    Naomi B Haas
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 98:1837-41. 2003
    ..Estramustine has been shown to potentiate the antimicrotubule effects of vinblastine. The authors sought to increase the activity of vinblastine in RCC through the addition of estramustine...
  9. ncbi Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model
    Raymond S McDermott
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Support Oncol 4:524-9. 2006
    ..75. The incidence of clinically significant renal deterioration in patients treated with zoledronic acid is low.We present a predictive model for decision support when estimating this risk...
  10. ncbi mTOR as a target for therapy of renal cancer
    Gary R Hudes
    Genitourinary Malignancies Program, Fox Chase Cancer Center, Philadelphia, PA, USA
    Clin Adv Hematol Oncol 5:772-4. 2007
  11. pmc Serum amino acid levels as a biomarker for renal cell carcinoma
    Aladdin Mustafa
    Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 186:1206-12. 2011
    ..Therefore, we investigated whether serum amino acid profiles are a potentially useful biomarker in patients with renal cell carcinoma...
  12. pmc Global reactivation of epigenetically silenced genes in prostate cancer
    Ilsiya Ibragimova
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer Prev Res (Phila) 3:1084-92. 2010
    ..Further study of the hypermethylome will provide insight into the biology of the disease and facilitate translational studies in prostate cancer...
  13. ncbi Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study
    Naomi B Haas
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 9:109-14. 2003
    ..We conducted a Phase II trial of bryostatin-1, an inhibitor of protein kinase C, in advanced renal cell carcinoma to measure toxicity, response rate, time to progression, and induction of cytokines...
  14. pmc Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma
    Jianming Pei
    Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Genes Chromosomes Cancer 49:610-9. 2010
    ..These findings also suggest that the 5q duplication/3p deficiency resulting from unbalanced 3;5 translocations conveys a proliferative advantage of particular importance in ccRCC tumorigenesis...
  15. ncbi Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials
    Andre Rogatko
    Departments of Biostatistics and Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 10:4645-51. 2004
    ..Mixed model ANOVA was used to model TI on the basis of data from all trials using a specific agent. Generalized estimating equations in the context of binary logistic regression were used to model dose-limiting toxicity...
  16. ncbi Selecting targeted therapies for patients with renal cell carcinoma
    Elizabeth R Plimack
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Natl Compr Canc Netw 9:997-1006; quiz 1007. 2011
    ..These recommendations should supplement the current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of advanced RCC...
  17. ncbi Cranial nerve deficits in patients with metastatic prostate carcinoma: clinical features and treatment outcomes
    Raymond S McDermott
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 101:1639-43. 2004
    ..Cranial nerve lesions due to metastases from prostate carcinoma to the skull base are an uncommon yet clinically significant finding...